Exercise and nicotinic acid delayed action drug - enduracin: application in outpatient rehabilitation of patients with ischemic heart disease

• Published in: Terapevtic̆eskii arhiv Vol. 79; no. 4; pp. 54 - 59
• Main Authors: R G Oganov, D M Aronov, V В Krasnitsky, N V Perova, A M Olferyev, A V Smolensky, N K Novikova, V A Vygodin
• Format: Journal Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 01.04.2004
• Subjects: coronary heart disease; dyslipidemia; ejection fraction; enduracin; exercise
• ISSN: 0040-3660; 2309-5342

Aim. To evaluate efficacy of combined use of moderate exercise and nicotinic acid drug enduracin in patients with coronary heart disease (CHD) with moderate dyslipidemia (DE). Material and methods. The effects of exercise therapy alone, enduracin alone and their combination on physical performance (PP), hemodynamics, blood lipid spectrum and clinical course of CHD were studied in 93 CHD patients with moderate DE. The results were evaluated clinically after 1-year treatment. Results. Combined used of exercise and enduracin in CHD patients showed its efficacy manifesting in improvement of PP, hemodynamics at rest and exercise test, left ventricular systolic function, clinical course, reduction of DE. Enduracin+exercise appeared more efficient than their use in monotherapy. Enduracin monotherapy had a positive action on PP, arterial pressure and anginal attacks frequency. Conclusion. Enduracin is recommended as monotherapy and in combination with moderate exercise in outpatient rehabilitation and secondary prophylaxis of CHD patients with moderate dyslipidemia and angina pectoris to relieve myocardial ischemia under exercise, to raise PP, improve lipid composition of blood and prevent maladaptive left ventricular remodeling.